Strategies for Using Computational Toxicology Methods in Pharmaceutical R&D

Computational Toxicology: Risk Assessment for Pharmaceutical and Environmental Chemicals

Volumn , Issue , 2006, Pages 545-579

  Müller, Lutz ^a   Breidenbach, Alexander ^a   Funk, Christoph ^a   Muster, Wolfgang ^a   Pähler, Axel ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Drug induced adverse drug reactions (ADRs); Local versus global SAR models; Toxicology and ADME assays and expectations

Indexed keywords

EID: 37849025261     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470145890.ch19     Document Type: Chapter

References (89)

1. Dipple A. DNA adducts of chemical carcinogens. Carcinogenesis 1995;16:437-41.
2. Uetrecht J. Role of drug metabolism for breaking tolerance and the localization of drug hypersensitivity. Toxicology 2005;209:113-8.
3. Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005;35:325-61.
4. Nelson SD. Structure toxicity relationships-How useful are they in predicting toxicities of new drugs? Adv Exp Med Biol 2001;500:33-43.
5. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, O'Donnell JP, Boer J, Harriman SP. A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 2005;6:161-225.
6. Zhou S, Chan E, Duan W, Huang M, Chen YZ. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev 2005; 37:41-213.
7. Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, Ness D, May PC. Safety, tolerability, and changes in amyloid b concentrations after administration of a g-secretase inhibitor in volunteers. Clin Neuropharmacol 2005; 28:126-32.
8. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, Ciaccio PJ. Modulation of Notch processing by g-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Tox Sci 2004;82:341-58.
9. De Smedt M, Hoebeke I, Reynvoet K, Leclercq G, Plum J. Different thresholds of Notch signaling bias human precursor cells toward B-, NK-, monocytic/dendritic-, or T-cell lineage in thymus microenvironment. Blood 2005;108:3498-506.
10. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJJ, Zhang L, Higgins GA, Parker EM. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004;279:12876-82.
11. Maillard I, Fang T, Pear WS. Regulation of lymphoid development, differentiation and function by the Notch pathway. An Rev Immunol 2005;23:945-74.
12. Dobler M, Lill MA, Vedani A. From crystal structures and their analysis to the in silico prediction of toxic phenomena. Helv Chim Acta 2003;86:1554-68.
13. Caldwell GW, Yan Z. Screening for reactive intermediates and toxicity assessment in drug discovery. Curr Opin Drug Discov Devel 2006;9:47-60.
14. Yamashita F, Hashida M. In silico approaches for predicting ADME properties of drugs. Drug Metab Pharmacokinet 2004;19:327-38.
15. Hatch FT, Colvin ME. Quantitative structure-activity (QSAR) relationships of mutagenic aromatic and heterocyclic amines. Mutat Res 1997;376:87-96.
16. Sabbioni G. Hemoglobin binding of aromatic amines: molecular dosimetry and quantitative structure-activity relationships for N-oxidation. Environ Health Perspect 1993;99:213-6.
17. Baillie TA, Davis MR. Mass spectrometry in the analysis of glutathione conjugates. Biol Mass Spectrom 1993;22:319-25.
18. Baillie TA, Kassahun K. Biological reactive intermediates in drug discovery and development: a perspective from the pharmaceutical industry. Adv Exp Med Biol 2001;500:45-51.
19. Day SH, Mao A, White R, Schulz-Utermoehl T, Miller R, Beconi MG. A semiautomated method for measuring the potential for protein covalent binding in drug discovery. J Pharmacol Toxicol Meth 2005;52:278-85.
20. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 2004;17:3-16.
21. Yan Z, Rafferty B, Caldwell GW, Masucci JA. Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses. Eur J Drug Metab Pharmacokinet 2002;27:281-7.
22. Smith DA, Obach RS. Seeing through the mist: Abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab Dispos 2005;33:1409-17.
23. Lin J, Sahakian DC, de Morais SMF, Xu JJ, Polzer RJ, Winter SM. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem 2003;3:1125-54.
24. Garattini S. Drug metabolism: from experiments to regulatory aspects. Exp Toxic Pathol 1996;48(Suppl II):142-51.
25. Eddershaw PJ, Beresford AP, Bayliss MK. ADME/PK as part of a rational approach to drug discovery. Drug Discov Today 2000;5(9):409-14.
26. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, Shipley LA. Drug metabolites in safety testing. Toxicol Appl Pharmacol 2002;182:188-96.
27. Lipinksi CM, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26.
28. Richard AM, Williams CR. Distributed structure-searchable toxicity (DSSTox) public database network: A proposal. Mutat Res 2002;499:27-52.
29. Kirkland D, Aardema M, Henderson L, Müller L. Evaluation of the ability of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens: I. Sensitivity, specificity and relative predictivity. Mutat Res 2005;584:1-257.
30. Judson PN, Cooke PA, Doerrer NG, Greene N, Hanzlik RP, Hardy C, Hartmann A, Hinchcliffe D, Holder J, Müller L, Steger-Hartmann T, Rothfuss A, Smith M, Thomas K, Vessey JD, Zeiger E. Towards the creation of an international toxicology information centre. Toxicology 2005;213:117-28.
31. Sanderson DM, Earnshaw CG. Computer prediction of possible toxic action from chemical structure. Hum Exp Toxicol 1991;10:261-73.
32. Greene N, Judson PN, Langowski JJ, Marchant CA. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR, and METEOR. SAR & QSAR. Environ Res 1999;10:299-313.
33. Klopman G, Rosenkranz H. Approaches to SAR in carcinogenesis and mutagenesis-Prediction of carcinogenicity/mutagenicity using Multi-Case. Mutat Res 1994;305(1):33-46.
34. Matthews EJ, Contrera JF. A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software. Regul Toxicol Pharmacol 1998;28(3):242-64.
35. Redfern WS, Wakefield ID, Prior H, Pollard CE, Hammond TG, Valentin, J-P. Safety pharmacology-A progressive approach. Fundam Clin Pharmacol 2002;16:161-73.
36. ICH S7A, Safety pharmacology studies for human pharmaceuticals. 2000 http://www.ich.org.
37. Crumb W, Cavero I. QT interval prolongation by non-cardiovascular drugs: Issues and solutions for novel drug development. Pharm Sci Technol Today 1999; 2:270-80.
38. Shah RR. Drugs, QT interval prolongation and ICH E14: The need to get it right. Drug Saf 2005;28:115-25.
39. Fung MC, Hsiaohui Wu H, Kwong K, Hornbuckle K, Muniz E. Evaluation of the profile of patients with QTc prolongation in spontaneous adverse event reporting over the past three decades-1969-98. Pharmacoepidemiol Drug Saf 2000;9 (Suppl 1):S24.
40. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: Implications for drug approval and labelling. Drug Saf 2001;24:323-51.
41. Dessertenne F. La tachycardie ventriculaire à deux foyers opposes variable. Arch Mal Coeur Vaiss 1996;59:263-72.
42. Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F. QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development. Med Res Rev 2005;25:133-66.
43. ICH E14. The clinical evaluation of QT/QTc interval prolongation and proar-rhythmic potential for nonantiarrhythmic drugs. 2005. http://www.ich.org.
44. ICH S7B. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. 2005. http://www.ich.org.
45. Bennett PB, Guthrie HR. Trends in ion channel drug discovery: Advances in screening technologies. Trends Biotechnol 2003;21:563-9.
46. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110:904-10.
47. Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol 2002;54:188-202.
48. Muzikant AL, Penland RC. Models for profiling the potential QT prolongation risk of drugs. Curr Opin Drug Discov Devel 2002;5:127-35.
49. Bottino D, Penland RC, Stamps A, Traebert M, Dumotier B, Georgiva A, Helmlinger G, Lett GS. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart. Prog Biophys Mol Biol 2006;90:414-43.
50. Noble D. Systems biology and the heart. Biosystems 2006;83:75-80.
51. Ekins S, Crumb WJ, Sarazan RD, Wikel JH, Wrighton SA. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J Pharmacol Exp Ther 2002;301:427-34.
52. Cavalli A, Poluzzi E, De Ponti F, Recanatini M. Toward a pharmacophore for drugs inducing the long QT syndrome: Insights from a CoMFA study of HERG K(+) channel blockers. J Med Chem 2002;45:3844-53.
53. Keserü GM. Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett 2003;13:2773-5.
54. Krejsa CM, Horvath D, Rogalski SL, Penzotti JE, Mao B, Barbosa F, Migeon JC. Predicting ADME properties and side effects: The BioPrint approach. Curr Opin Drug Discov Devel 2003;6:470-80.
55. Johnson DE, Rodgers AD. Computational toxicology: Heading toward more relevance in drug discovery and development. Curr Opin Drug Discov Devel 2006;9:29-37.
56. Pearlstein RA, Vaz RJ, Kang J, Chen XL, Preobrazhenskaya M, Shchekotikhin AE, Korolev AM, Lysenkova LN, Miroshnikova OV, Hendrix J, Rampe D. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett 2003;13:1829-35.
57. Roche O, Trube G, Zuegge J, Pflimlin P, Alanine A, Schneider G. A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. Chembiochem 2002;3:455-9.
58. Ekins S. In silico approaches to predicting drug metabolism, toxicology and beyond. Biochem Soc Trans 2003;31:611-4.
59. Sun H. An accurate and interpretable Bayesian classification model for prediction of hERG liability. Chem Med Chem 2006;1:315-22.
60. Mitcheson JS, John S, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000; 97(22):12329-33.
61. Yap CW, Cai CZ, Xue Y, Chen YZ. Prediction of torsade-causing potential of drugs by support vector machine approach. Toxicol Sci 2004;79:170-7.
62. Gepp MM, Hutter MC. Determination of hERG channel blockers using a decision tree. Bioorg Med Chem 2006;14:5325-32.
63. Aronov AM. Predictive in silico modeling for hERG channel blockers. Drug Discov Today 2005;10(2):149-55.
64. Muster W, Albertini S, Gocke E. Structure-activity relationship of oxadiazoles and allylic structures in the Ames test: An industry screening approach. Mutagenesis 2003;18(4):321-9.
65. Albertini S, Bös M, Bos M, Gocke E, Kirchner S, Muster W, Wichmann J. Suppression of mutagenic activity of a series of 5HT2c receptor agonists by the incorporation of a gem-dimethyl group: SAR using the Ames test and a DNA unwinding assay. Mutagenesis 1998;13(4):397-403.
66. Muster W, Chételat AA, Kirchner S, Rothfuss A, Albertini S, Speit G, Gocke E. Mutagenicity testing and investigations on the mechanism of genotoxicity for a NMDA receptor antagonist. In Preparation.
67. Snyder RD, Pearl GS, Mandakas G, Choy WN, Goodsaid F, Rosenblum IY. Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules. Environ Mol Mutagen 2004;43:143-58.
68. Cronin MTD, Manga N, Seward JR, Sinks GD, Schultz TW. Parametrization of electrophilicity for the prediction of the toxicity of aromatic compounds. Chem Res Toxicol 2001;14(11):1498-505.
69. Franke R, Gruska A, Giuliani A, Benigni R. Prediction of rodent carcinogenicity of aromatic amines: A quantitative structure-activity relationships model. Carcinogenesis 2001;22(9):1561-71.
70. Benigni R, Passerini L. Carcinogenicity of the aromatic amines: from structure-activity relationships to mechanisms of action and risk assessment. Mutat Res 2002;511:191-206.
71. Müller L, Mauthe RJ, Riley CM, Andino MM, De Antonis D, Beels C, DeGeorge J, De Knaep AGM, Ellison D, Fagerland JA, Frank R, Fritschel B, Galloway S, Harpur E, Humfrey CDN, Jacks AS, Jagota N, Mackinnon J, Mohan G, Ness DK, O'Donovan MR, Smith MD, Vudathala G, Yotti L. A rationale for determination, testing and control of genotoxic impurities in pharmaceuticals. Regul Toxicol Pharmacol 2006;44:198-211.
72. Spielmann H, Balls M, Dupuis J, Pape WJ, Pechovitch G, De Silva O, Holzhutter HG, Clothier R, Desolle P, Gerberick F, Liebsch M, Lovell WW, Maurer T, Pfan-nenbecker U, Potthast JM, Csato M, Sladowski D, Steiling W, Brantom P. The international EU/COLIPA in vitro phototoxicity validation study: Results of phase II (blind trial): Part 1. The 3T3 NRU phototoxicity test. Toxicol In Vitro 1998;12(3):305-27.
73. Gocke E, Albertini S, Chetelat AA, Kirchner S, Muster W. The photomutagenicity of fluoroquinolones and other drugs. Toxicol Lett 1998;102-3:375-81.
74. Gocke E, Chetelat AA, Csato M, McGarvey DJ, Jakob-Roetne R, Kirchner S, Muster W, Potthast M, Widmer U. Phototoxicity and photogenotoxicity of nine pyridone derivatives. Mutat Res 2003;535(1):43-54.
75. Uetrecht JP. Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions? Curr Drug Metab 2000;1:133-41.
76. Ju C, Uetrecht JP. Mechanism of idiosyncratic drug reactions: Reactive metabolites formation, protein binding and the regulation of the immune system. Curr Drug Metab 2002;3:367-77.
77. Smith MT. Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol 2003;16:679-87.
78. Narayanan PK, Hart T, Elcock F, Zhang C, Hahn L, McFarland D, Schwartz L, Morgan DG, Bugelski P. Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: A flow cytometric assessment. Cytometry A 2003;52:28-35.
79. Tirmenstein MA, Hu CX, Gales TL, Maleeff BE, Narayanan PK, Kurali E, Hart TK, Thomas HC, Schwartz LW. Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol Sci 2002;69:131-8.
80. Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of trogli-tazone as a possible factor contributing to troglitazone-induced hepatotoxicity: In vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001;59:627-35.
81. Menon KVN, Angulo P, Lindor KD. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. Am J Gastroenterol 2001;96:1631-4.
82. Fischer H., Kansy M, Potthast M, Csato M. Predition of in vitro phospholipidosis of drugs by means of their amphiphilic properties. In: Höltjc H-D and Sippl W, editors. Proceedings of the 13th European Symposium on QSAR: Application in chemometrics, Barcelona, Spain. 27 August-1 September 2000. Barcelona: Prous Science, 2001. p. 286-9.
83. Fischer H, Kansy M, Bur D. CAFCA: A novel tool for the calculation of amphiphilic properties of charged drug molecules. Chimica 2000;54(11):640-5.
84. CHMP (2006) Guideline on the limits of genotoxic impurities (CHMP/SWP/5199/02, June 2006).
85. Muehlbacher JP, Ertl P, Selzer P, Müller L, Glowienke S, Schuffenhauer A. Toxi-zitätsvorhersage im Intranet. Nachrichten aus der Chemie 2004;52:162-4.
86. Yang C, Richard AM, Cross KP. The art of data mining the minefields of toxicity databases to link chemistry to biology. Curr Comput Aided Drug Des 2006;2:135-50.
87. Matthews EJ, Kruhlak NL, Cimino MC, Benz RD, Contrera JF. An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants and carcinogens using in silico methods. Regul Toxicol Pharmacol 2006;44:97-110.
88. Contrera JF, Matthews, EJ, Kruhlak, NL, Benz RD. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. Regul Toxicol Pharmacol 2004;40:185-206.
89. FDA. Draft Guideline for industry: Safety testing of drug metabolites. US FDA, CDER June 2005.